IDH2 and glioblastoma: Furthermore, proteomic profiling has distinguished IDH1-mutant from IDH1-wildtype GBM by revealing specific metabolic protein alterations, such as increased expression of aldehyde dehydrogenase 1 family member A3 (ALDH1A3) and IDH1-R132H in IDH-mutant tumors, underscoring the relevance of metabolic reprogramming in gliomagenesis [40].